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Introduction: Multiple studies have reported genetic associations with prognostic
outcomes of urinary bladder cancer. However, the lack of replication of these associations
prohibits establishing further evidence-based research directions. Moreover, there is a
lack of independent bladder cancer patient samples that contain prognostic measures,
making genetic replication analyses even more challenging.
Materials and Methods: We have identified 1,534 eligible patients and used data
on Hospital Episode Statistics in the UK Biobank to model variables of otherwise
non-collected events on bladder cancer recurrence and progression. Data on survival
was extracted from the Death Registry. We have used SNPTEST software to replicate
previously reported genetic associations with bladder cancer recurrence (N = 69),
progression (N = 23), survival (N = 53), and age at the time of diagnosis (N = 20).
Results: Using our algorithm, we have identified 618 recurrence and 58 UBC
progression events. In total, there were 209 deaths (106 UBC-specific). In replication
analyses, eight SNPs have reached nominal statistical significance (p < 0.05).
Rs2042329 (CWC27) for UBC recurrence; rs804256, rs4639, and rs804276 (in/close
to NEIL2) for NMIBC recurrence; rs2293347 (EGFR) for UBC OS; rs3756712 (PDCD6)
for NMIBC OS; rs2344673 (RGS5) for MIBC OS, and rs2297518 (NOS2) for
UBC progression. However, none have remained significant after adjustments for
multiple comparisons.
Discussion: External replication in genetic epidemiology is an essential step to identify
credible findings. In our study, we identify potential genetic targets of higher interest for
UBC prognosis. In addition, we propose an algorithm for identifying UBC recurrence and
progression using routinely-collected data on patient interventions.
Keywords: bladder cancer, SNP, replication, UK Biobank, prognosis
INTRODUCTION
Urinary bladder cancer (UBC) is a disease of great burden; yet the diagnosis, clinical
management, and patient survivorship has changed little over the last few decades (1, 2).
Genetic studies may provide important clues on biological pathways underlying the development
of UBC. Importantly, advances in understanding what drives a favorable UBC prognosis
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could aid in predicting patient outcomes. As a result, and
informed and timely patient stratification would allow an
individually-tailored cancer management plan, which is
likely to better reflect patient needs than current group-level
recommendations (3).
Multiple genetic associations with UBC prognostic outcomes
(e.g., survival, recurrence) have been reported in the literature
(Lipunova et al., under review). However, the number of potential
genetic clues far exceeds the available resources for clinical and
functional investigation. As such, the scientific community must
take an approach of targeting most-promising associations first.
There aremultiple ways to define clinical relevance of a genetic
variant, including external replication to reduce the chance of
false-positives (4, 5). However, replication of genetic associations
includes many hurdles, such as a lack of independent participant
cohorts with adequate sample sizes. Moreover, focus on a sub-
phenotype (e.g., recurrence) makes it even more difficult due to
required additional sources of data (e.g., hospital records).
Increased availability of population-based electronic health
records can help to alleviate the burden of investigating
diseases for which adequate sample sizes are difficult to
acquire. UK Biobank is the largest population-based cohort in
the United Kingdom and serves as a powerful resource for
investigating genetic associations (6) and has not yet been widely
used for investigating UBC. The presence of Hospital Episode
Statistics (HES) in the UK Biobank offers an unprecedented
opportunity to use these data to identify UBC recurrence
and progression events, that are not a part of the usually-
collected information.
In the current study, we have aimed to identify UBC patients
in the UK Biobank and use HES statistics to construct prognostic
events. We have further used this data to externally replicate
previously reported genetic associations on UBC survival,
recurrence, and age at the time of diagnosis.
MATERIALS AND METHODS
SNP Selection
We have aimed to replicate all SNPs that have been previously
associated with UBC recurrence, progression, death (overall
or cancer-specific), and age at the time of diagnosis. The
polymorphisms were extracted from a recent review on
prognostic UBC outcomes (Lipunova et al., under review). To
capture any associations reported since the review, we have
updated the list of SNPs by querying PubMed database for
new articles using identical search terms to those used in the
review (Figure 1). The search was limited to articles published
in English language between 13th November 2018 and 19th
February 2019. Eleven papers were identified in total, with one
study being eligible for inclusion (7). Additionally, we have
included associations for age at the time of diagnosis from a
genome-wide association study (GWAS) previously carried out
in the Bladder Cancer Prognosis Programme (BCPP) (8).
After removing duplicate entries, there were 69 SNPs to test
for recurrence, 53 for survival, 20 for age, and 23 for progression
(Supplementary Tables 1–4).
Study Population
UK Biobank is a population-based cohort in the UK, having
collected genetic and clinical data on over 500,000 participants,
aged 40–69 at the time of recruitment in 2006–2010. The design,
data collection and processing are described in detail elsewhere
(6, 9).
Our analysis was restricted to UBC patients (corresponding
International Classification of Diseases (ICD) codes of C67.0,
C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9,
D09.0 (ICD10) and 1880, 1882, 1884, 1886, 1888, 1889, 2337
(ICD9). To prevent bias from analyzing heterogeneousmolecular
UBC subtypes, histology was limited to the following ICD-O
(ICD Oncology) codes: 8000 (Neoplasm), 8001 (Tumor cells),
8010 (Carcinoma), 8020 (Carcinoma, undifferentiated), 8050
(Papillary carcinoma), 8120 (Transitional cell carcinoma), and
8130 (Papillary transitional cell carcinoma).
HES contains admitted in-patient data starting with 1997 (10)
and includes data on patients both under National Health Service
(NHS) and private care. HES data is provided to the UK Biobank
on an annual basis, covering the past financial year (starting
1st April of each year). In our analyses, the follow-up covers
all in-hospital interventions registered until March 31st, 2017.
Operative procedures use OPCS4 (Office of Population, Censuses
and Surveys: Classification of Interventions and Procedures,
Version 4) coding system.
In total, there were 1,534 UBC patients with clinical and
genetic data available for analysis.
Outcomes
Age
Age at the time of diagnosis was modeled both as a continuous
and categorical variable.
To replicate previous associations as accurately as possible, we
have dichotomised age variables using the cut-off points reported
in the original research articles (≥/<50, 55, 60, 65, and 70 years,
Supplementary Table 3).
Death
Death was modeled as an overall (death vs. no death) or a UBC-
specific event (death vs. no death, when primary cause of death
was assigned C67-(ICD10) or 188-related (ICD9) codes).
Recurrence
The events of bladder recurrence and progression are not part
of the routinely collected data in the Cancer Registry, or other
national/regional datasets. However, the HES in the UK Biobank
make it possible to identify a fraction of these events using
proxy data.
For recurrence, we have considered three conditions to be
representative of an event (Figure 2). First, a transurethral
resection of a bladder tumor (TURBT) (OPCS4 code M42)
is regarded to be enough to signify a UBC event. Secondly, a
time gap of longer than 4 months between chemotherapeutic
treatments into urinary bladder (OPCS4 codes M494/M495)
was considered to be substantial to correspond to two different
events. Thirdly, we have assumed a UBC diagnosis if an
examination of the urinary bladder (OPCS4 code M45) was
Frontiers in Oncology | www.frontiersin.org 2 October 2019 | Volume 9 | Article 1082
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FIGURE 1 | Selection process of the SNPs used in replication analyses.
led by an intervention within 6 months. Relevant interventions
were chemotherapeutic treatments into urinary bladder,
cystectomy, radiotherapy, and chemotherapy (corresponding
to OPCS4 codes of M494/M495, M34, X65, X72, X292,
X298, X308, X352, respectively). Currently presented list of
chemotherapy-related OPCS4 is not exhaustive, but rather
based on interventions observed in our data. Further
development of the algorithm is likely to adjust the list
as needed.
Progression
In our framework, all events of progression are recurrences
by default. However, we have considered adding additional
criteria would allow distinguishing which recurrences were also
representative of UBC progression. We have considered an event
of UBC progression to have taken place if either a TURBT
(OPCS4 code M42) or examination of the urinary bladder
(OPCS4 code M45) was followed by interventions of cystectomy
(OPCS4 code M34) and/or radiotherapy (OPCS4 code X65)
within 6 months (Figure 2).
To prevent registration duplicates, two recurrence and/or
progression events were considered independent of one another
if time in between the records was >3 months.
Invasiveness at the Time of Diagnosis
Finally, UBC clinical management is heavily dependent on
its’ invasiveness at the initial diagnosis. A UBC diagnosis
that was followed by either cystectomy or radiotherapy
was considered to represent a muscle-invasive bladder
cancer (MIBC), while the remaining diagnoses are held
to be non-muscle-invasive bladder cancer (NMIBC)
cases (Figure 2).
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FIGURE 2 | Conditions for modeled events of UBC recurrence, progression, and invasiveness at baseline (MIBC-muscle-invasive bladder cancer,
TURBT-transurethral resection of bladder tumor). All codes correspond to OPCS4 classification.
Ethics and Consent
All UK Biobank participants have provided informed consent.
Current research has been conducted using the UK Biobank
Resource under Application Number 42772.
Genotype Data Quality Control (QC) and
Imputation
Detailed procedures on QC and imputation in the UK Biobank
are described elsewhere (9).
To verify the high quality of all tested SNPs, we have extracted
imputation accuracy measures (INFO scores) and MAF (minor
allele frequencies) (Supplementary Table 5). INFO scores are
computed to estimate the level certainty of imputed SNPs. The
value ranges from 0 to 1, with estimates close to 1 representing
SNPs imputed with high accuracy (11).
To avoid population stratification bias, we have restricted our
sample to a homogenous group of White British participants, as
previously identified by the UK Biobank team (9).
Statistical Analysis
To test for an association between selected SNPs and UBC
recurrence, progression, death, and age, we have utilized
SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/
snptest/snptest.html). To estimate Linkage disequilibrium (LD),
an online tool was used (https://ldlink.nci.nih.gov/). LD defines
the correlation between alleles in a given population. Due to
some SNPs being in high LD, it might be difficult to establish
which allele is representing the cause, as they are often inherited
together. At the same time, linkage equilibrium suggests alleles
are inherited independent of one another. Logistic regression
Frontiers in Oncology | www.frontiersin.org 4 October 2019 | Volume 9 | Article 1082
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using allele dosages was applied to estimate odds ratios (OR) and
corresponding confidence intervals (CI) for death, recurrence,
progression, and categorical age events; while linear regression
was used to estimate the effect of age as a continuous variable. All
associations were tested under additive model of inheritance and
adjusted for participant sex. To reduce multiple testing, analyses
were ran for the outcome that resembled the originally-reported
association most closely (e.g., if a variant has been associated
with NMIBC recurrence, we have only tested NMIBC patients
instead of the whole UBC sample). To better estimate the
strength of evidence for replication results, we additionally
included calculation of the Bayes Factor (BF). In simple
terms, BF can be considered as a ratio of probabilities for two
competing hypotheses (for example, the probability of a SNP
being associated with an outcome vs. the SNP not influencing
the outcome). The ratio provides an estimate that shows the
extent of one hypothesis being more (or less) likely than the
alternative one. In contrast, the generically-used frequentist
approach (resulting in a p-value) evaluates the probability of
data under a specific hypothesis, which alone does not provide
indication of the association strength.
Variants in the replication were considered promising
if the nominal statistical significance (p-value) has reached
<0.05. Bonferroni adjustment per each outcome for multiple
comparisons resulted in statistical significance level (p-value) to
be 0.0007 for recurrence (α = 0.05/69), 0.002 for progression
(α = 0.05/23), 0.0009 for survival (α = 0.05/53), and 0.0025 for
age (α= 0.05/20).
RESULTS
In total, 1,534 UBC patients were available for replication
analyses of prognostic events (Table 1). Mean age of UBC
patients was 61 years, and most were males (78%). Using our
algorithm on HES data, we could identify UBC invasiveness at
baseline, recurrent, and progressive events for UBC patients in
the UK Biobank cohort. Majority of UBC cases were NMIBC
(93%). Death was recorded for 209 (13.6%) patients, out of which
106 were UBC-specific. In addition, we estimate 618 patients
(40%) have experienced a recurrence, and 58 (3.8%) have had a
UBC progression.
In the replication analyses, eight SNPs have reached a p-value
of <0.05 (Table 2). However, none of the variants remained
significant after applying Bonferroni-corrections for multiple
comparisons (corrected for each tested outcome).
Recurrence
Four of these SNPs were associated with bladder cancer
recurrence. Rs2042329 (CWC27) was linked to an increased
risk of UBC recurrence (OR = 1.26, 95% CI: 1.10; 1.48); while
rs804256, rs4639, and rs804276, all located in/close to NEIL2
were associated with NMIBC-only recurrence (OR = 1.23, 95%
CI: 1.05–1.43; OR = 1.20, 95%CI: 1.03–1.39; OR = 1.17, 95%
CI: 1.01–1.36, respectively). All SNPs that were associated with
recurrence showed consistent direction, but were more modest
in comparison to the original studies [HR = 1.54 (1.10–2.16) for
rs2042329 (12), HR = 4.58 (2.61–8.02) for rs804256 (13), HR =
TABLE 1 | Descriptive characteristics of the UBC patients from the UK Biobank.
N p-Value*
Sex 1,534 <0.001
Males (%) 1,197 (78.0)
Females (%) 337 (22.0)
Age [Mean (SD)] 61.3 (9.0)
Death 1,534 <0.001
No (%) 1,325 (86.4)
Yes (%) 209 (13.6)
UBC-specific death 1,534 <0.001
No (%) 1,428 (93.1)
Yes (%) 106 (6.9)
Recurrence 1,534 <0.001
No (%) 916 (59.7)
Yes (%) 618 (40.3)
Progression 1,534 <0.001
No (%) 1,476 (96.2)
Yes (%) 58 (3.8)
NMIBC at baseline 1,534 <0.001
No (%) 114 (7.4)
Yes (%) 1,420 (92.6)
*Chi-square test for group independence.
NMIBC, non-muscle-invasive bladder cancer; SD, standard deviation; UBC, urinary
bladder cancer.
2.60 (1.68–4.03) for rs4639 (13), and HR = 2.71 (1.75–4.20) for
rs804276 (13)].
Although SNPs rs804256, rs4639, and rs804276 all map to the
same locus, LD values imply they are independent results (R2 for
rs804276 and rs804256 = 0.09; R2 for rs804276 and rs4639 =
0.43; R2 for rs4639 and rs804256= 0.38).
Death
Three SNPs [rs2344673 (RGS5), rs3756712 (PDCD6), and
rs2293347 (EGFR)] were associated with events of bladder cancer
death, albeit in different subgroups. Rs2293347 (EGFR) was
associated with lower death rates among all UBC patients (OR=
0.69, 95% CI: 0.47–0.99), rs3756712 (PDCD6) was significant for
NMIBC patients (OR = 1.29, 95% CI: 1.02–1.63), and rs2344673
(RGS5) showed reduced rate of death among MIBC cases (OR=
0.22, 95% CI: 0.05–0.98).
In comparison to the original study, replicated SNPs in
PDCD6 showed effect in the same direction, but had a reduced
estimate [HR= 5.11 (1.43–18.22) (14)].
However, inconsistency in direction of the effect was observed
for SNPs in EGFR and RGS5 [HR = 1.5 (1.0–2.3) for rs2293347
(15) and HR= 1.55 (1.15–2.11) for rs2344673 (16)].
Progression
Carrying a minor allele of rs2297518 in NOS2 corresponded to
a lower chance of UBC progression (OR = 0.56, 95% CI: 0.32–
0.99). In the original study, rs2297518 was also associated with a
lower risk of progression [HR= 0.21 (0.05–0.87) (17)].
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Bayes factor was highest for the variant associated with
NMIBC recurrence in CWC27, reaching log10(BF) = 1.56. For
all remaining SNPs, Bayes statistic indicates replication sample
was low-powered (18), with log10(BF) ranging between 0 and 1.
DISCUSSION
In the current study, we describe an external replication of
previously reported genetic associations for UBC recurrence,
progression, death, and age at the time of diagnosis using HES
data available the UK Biobank.
The aim of our study is 2-fold. Firstly, mining routinely-
collected data for identifying complex phenotypes is inevitable
to become a common practice. In the light of current needs,
we propose an algorithm that identifies UBC recurrences and
progression events via recorded interventions in a hospital
setting. Current approach uses OPCS4 classification system, but
we are confident applied assumptions can be translated to other
globally-used systems (e.g., International Classification of Health
Interventions, ICHI). We acknowledge identified prognostic
events make up only a fraction of the true event volume, and are
likely to be an underestimate. The extent of the underestimation
requires testing the algorithm in an external cohort and is a
necessary subsequent step in refining the currently-described
approach. The level of underestimation is likely to vary for
differed outcomes, as some events are arguably easier to identify
(e.g., recurrence), while progression requires more detailed data
and is subject to a higher level of underrepresentation. However,
we saw an overestimation resulting in a greater rate of error and
data misrepresentation. Moreover, inclusion of other clinically-
relevant characteristics (tumor stage, grade) would increase the
accuracy of modeled prognostic events. The provisioned release
of such data in the UK Biobank (https://biobank.ctsu.ox.ac.
uk/crystal/exinfo.cgi?src=future_timelines) will provide further
opportunities of updating the algorithm. Naturally, our proposed
approach and assumptions are subjective by nature and we
encourage the expert field to contribute ideas to make the
assumptions more accurate.
Secondly, an external replication of genetic associations is a
rare endeavor. Unfortunately, as simply put by Kraft et al. (4),
“Genetic epidemiology learned the importance of replication the
hard way.” External validation studies perform at much lower
rates, which underscores the significance of such efforts (5).
Most genetic studies are still exploratory in nature, and false-
positive results are inevitable. By prioritizing evidence-based
targets, more resources can be allocated toward investigating
variants with better promise of true impact on human health.
For UBC recurrence, the strongest result was mapped to
CWC27. Previous study reported rs2042329 to correspond to
higher expression of CWC27 in bladder cancer cells (12).
Additional functional analyses showed CWC27 might affect
bladder carcinogenesis via apoptosis. Interestingly, the original
finding was made for Chinese patients, and authors failed to
replicate the significance of rs2042329 on bladder cancer risk
among Europeans (12). However, it is unknown if the lack of
effect was also present for recurrence.
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Additionally, it is surprising to see three SNPs in NEIL2 being
significant for NMIBC recurrence, especially keeping in mind the
low likelihood of successful replication. Despite the high number
of SNPs, strength of evidence for these associations is low, as
reflected in Bayes Factor. Nonetheless, they might be promising
targets in future replications. NEIL2 is involved in DNA repair
mechanisms, and research suggest it influences malignancies
beyond bladder cancer. Alterations in normal NEIL2 activity
most likely result in accumulated oxidative damage, as elegantly
presented by Benitez-Buelga et al. (19).
For UBC progression, the replicated variant maps to NOS2.
The gene has been specifically linked to progression of various
cancers (20, 21). It seems NOS2 affects multiple oncogenic
pathways that simultaneously affect tumor proliferation,
angiogenesis, chemoresistance, and cell migration (20, 21).
As for UBC survival, three replicated SNPs are located in
RGS5, PCDC6, and EGFR. Interestingly, a previous independent
replication of SNPs associated with UBC prognosis has also
successfully validated a variant in RGS5 (rs12035879) for
overall survival (OS) of MIBC cases (22). Comparison of two
external replications offers potential insights—for example, the
rs11585883 did not replicate in our study; however, another SNP
in RGS5 was successful, and associated with the same outcome
(MIBCOS). These findings may be seen as cumulative toward the
involvement of RGS5 in cancer survival, even if specific SNPs are
yet to be identified. We have checked if previously and current
replicated RGS5 SNPs are in LD, and they seem to represent
independent signals in the gene (R2 = 0.03 for rs12035879
and rs2344673 among Europeans). One major weakness of the
replicated rs2344673 in our study is small sample size (29 cases
and 109 controls). A post-hoc analysis on the overall survival of
the whole sample, regardless of UBC invasiveness (209 cases and
1,325 controls) was not significant (data not shown). RGS5 may
not be relevant for all UBC patients, or might reflect power issues,
which highlights further investigation being essential.
Remaining two genes implicated in UBC and NMIBC
survival, namely EGFR and PDCD6, are both well-known cancer
genes (14, 23). PDCD6 seems to be heavily involved in apoptosis
(14); however, the exact role of PDCD6 is contrasting between
various cancers (24), and further molecular research will help
making evidence-based interpretations.
A replicated SNP (rs2293347) in EGFR has also previously
corresponded to a protective effect on survival of lung cancer
patients (25). The effect may be due to higher responsiveness
to chemotherapy (26), which is a worthwhile investigation in
future analyses.
Or study is subject to limitations, with one of the largest
drawbacks being the difference between founders’ and replication
cohorts. A lot of studies have investigated populations of non-
European ancestry, and it is possible we are not able to observe a
true effect due to differences in LD of candidate SNPs in different
samples. At the same time, the most reliable replication in our
study was rs2042329, first reported in a Chinese population (12).
None of our replicated SNPs have passed the Bonferroni-
corrected statistical significance level, suggesting some promising
SNPs may have been identified by chance. Furthermore, current
analyses have only focused on estimating the overall risk of a
prognostic event, without considering the relevance of elapsed
time to event. We see such and other more sophisticated analyses
as a further direction in utilizing the described approach.
We were also unable to reliably estimate assigned treatment
for UBC patients in the UK Biobank cohort, which would
unquestionably confer to a more precise replication analysis.
However, as the detail of released HES is increasing, we do
not see this data out of reach and likely to include in future
algorithm updates.
Finally, some replicated SNPs showed a conflicting direction
of effect when compared to the original studies. These issues are
likely to be clarified once more studies can confirm the overall
association and establish the effect specifics.
To summarize, we have carried out an external replication
of previously reported SNPs for UBC recurrence, progression,
death and age using a novel approach of identifying clinically-
relevant outcomes using HES data. Our analysis suggests
specific targets, namely CWC27, NEIL2, PDCD6, EGFR, and
NOS2, might be prioritized in efforts to further study the
role of genetics in UBC prognosis. We are cautious about
our findings, as there is no one metric or design to provide
unquestionable evidence; instead, it should be viewed as
one of the studies in a long line of accelerating research
on UBC.
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